The Motley Fool Previous Page

Can This Slumping Big Pharma Stock Make a Comeback?

Dan Carroll
October 25, 2013

AstraZeneca (NYSE: AZN) has been anything but a top stock lately. This big pharma member has seen sales slump by 15% in its most recent fiscal year alone, part of a huge hit from the patent cliff that continues to hamper the company's future outlook. The stock's only gained around 8% year-to-date, far less than some of its more accomplished rivals that have managed to beat back the worst of the patent cliff in recent quarters.

The future isn't looking much brighter right now, as AstraZeneca's suffering from a lackluster pipeline and further projected sales declines next year. AstraZeneca has looked around t